IP Library › Granted Patent US 11,896,569
Granted Patent B2
US 11,896,569 · App. 17/515,155 · Granted Feb 13, 2024

Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy

Inventor: Paolo Luca Maria Giorgetti (Milan, IT)
Assignee: Professional Dietetics S.p.A.
A61K31/198A61K31/375A61K31/405A61K31/4172A61K31/4415A61K31/51A61K47/38A61P1/04A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,896,569
App. No.
17/515,155
Granted
Feb 13, 2024
Kind
B2
Abstract

Amino acid composition for use in the treatment of mucositis in patients suffering from head and neck cancer, undergoing radiation therapy and/or chemotherapy, the composition comprising an active agent, the active agent comprising the amino acids: glutamine, leucine, isoleucine, valine, lysine, threonine, histidine, phenylalanine, methionine, tryptophan, tyrosine, and cystine, wherein the glutamine:leucine weight ratio is in the range 4.3 to 5.3.

Claims (22)

1. A method of treating mucositis in a patient who is suffering from neoplasia of the cervical-cephalic region and who is undergoing radiation therapy and/or chemoradiotherapy, the method consists of:

(1) selecting an amino acid composition for use in the treatment of mucositis in the patient who is suffering from neoplasia of the cervical-cephalic region and who is undergoing radiation therapy and/or chemoradiotherapy, the amino acid composition consists of:

(i) an active agent, said active agent consists of the amino acids glutamine, leucine, isoleucine, valine, lysine, threonine, histidine, phenylalanine, methionine, tryptophan, tyrosine, and cystine, wherein

(a) the amino acid composition is free of any further different amino acids,

(b) the glutamine:leucine weight ratio is in the range 4.3 to 5.3, and

(c) glutamine is present in an amount between 50 and 65% by weight with respect to the total weight of the active agent, and

(ii) optionally at least one of, none of which have any amino acids: carbohydrates, at least one thickening agent, at least one vitamin, pharmaceutically acceptable excipients, and flavouring substances, and

(2) administering the amino acid composition to the patient to treat mucositis in the patient who is suffering from neoplasia of the cervical-cephalic region and who is undergoing radiation therapy and/or chemoradiotherapy.

2. The method according to claim 1 , wherein the leucine:isoleucine:valine weight ratio is equivalent to 2:1:1.

3. The method according to claim 1 , wherein

the isoleucine:leucine weight ratio is in the range 0.2-0.7, and/or

the valine:leucine weight ratio range is in the range 0.2-0.8.

4. The method according to claim 1 , wherein

the threonine:leucine weight ratio is in the range 0.15-0.50, and/or

the lysine:leucine weight ratio is in the range 0.15-0.60.

5. The method according to claim 1 , wherein the at least one thickening agent is selected from the group consisting of xanthan gum, cellulose and derivatives thereof, konjak gum, konjak glucomannan, Arabic gum, modified starches.

6. The method according to claim 1 , wherein the at least one vitamin is selected from vitamin B 1 , vitamin B 6 , vitamin C.

7. The method according to claim 1 , wherein the glutamine is present in an amount between 55 and 60% by weight with respect to the total weight of the active agent.

8. The method according to claim 3 , wherein the isoleucine:leucine weight ratio is between 0.4-0.6.

9. The method according to claim 3 , wherein the valine:leucine weight ratio range is between 0.4-0.7.

10. The method according to claim 4 , wherein the threonine:leucine weight ratio is between 0.20-0.45.

11. The method according to claim 4 , wherein the lysine:leucine weight ratio is between 0.30-0.55.

Priority Claims (1)
IT 102015000015060 · May 14, 2015 · national
Continuity (2)
Continuation 15571130
Related Publication 20220047539A1 · Feb 17, 2022